TEVA
Teva Pharmaceutical Industries Ltd.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$41.96
+0.26%Year over year
Reported trailing growth
- Revenue
- +2.7%
- EBITDA
- -47.5%
- EBIT
- -0.7%
- EPS
- -28.6%
- Free cash flow
- +113.8%
- Operating cash flow
- +66.0%
Forward estimates
Based on analyst estimates
- Revenue
- -1.5%
- EBITDA
- +168.6%
- EPS
- +552.0%
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- +42.0%
- EBIT
- +123.2%
- Net income
- +186.0%
- EPS
- +184.8%
- Free cash flow
- +3.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026